title: MicroRNAs are potential therapeutic targets in fibrosing kidney disease: lessons from animal models.
abstract: Chronic disease of the kidneys has reached epidemic proportions in industrialized nations. New therapies are urgently sought. Using a combination of animal models of kidney disease and human biopsy samples, a pattern of dysregulated microRNA expression has emerged which is common to chronic diseases. A number of these dysregulated microRNA have recently been shown to have functional consequences for the disease process and therefore may be potential therapeutic targets. We highlight microRNA-21, the most comprehensively studied microRNA in the kidney so far. MicroRNA-21 is expressed widely in healthy kidney but studies from knockout mice indicate it is largely inert. Although microRNA-21 is upregulated in many cell compartments including leukocytes, epithelial cells and myofibroblasts, the inert microRNA-21 also appears to become activated, by unclear mechanisms. Mice lacking microRNA-21 are protected from kidney injury and fibrosis in several distinct models of kidney disease, and systemically administered oligonucleotides that specifically bind to the active site in microRNA-21, inhibiting its function, recapitulate the genetic deletion of microRNA-21, suggesting inhibitory oligonucleotides may have therapeutic potential. Recent studies of microRNA-21 targets in kidney indicate that it normally functions to silence metabolic pathways including fatty acid metabolism and pathways that prevent Reactive Oxygen Species generation in peroxisomes and mitochondria in epithelial cells and myofibroblasts. Targeting specific pathogenic microRNAs in a specific manner is feasible in vivo and may be a new therapeutic target in disease of the kidney.
authors.affiliation: Division of Nephrology, Departments of Medicine & Pathology, University of Washington, Seattle, Washington, USA ; Center for Lung Biology, University of Washington, Seattle, Washington, USA ; Institute of Stem Cell & Regenerative Medicine, University of Washington, Seattle, Washington, USA.
authors.forename: Jeremy S
authors.initials: JS
authors.lastname: Duffield
authors.affiliation: Division of Transplantation, Lahey Clinic Medical Center, Burlington ; Tufts University, Boston, Massachusetts, USA.
authors.forename: Monica
authors.initials: M
authors.lastname: Grafals
authors.affiliation: Division of Nephrology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
authors.forename: Didier
authors.initials: D
authors.lastname: Portilla
keywords: PPARα; ROS; chronic allograft dysfunction; chronic kidney disease; fibrosis; microRNA